ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

US High Court Invalidates Prometheus Patents On Medical Diagnostic Tests

By Brent Kendall Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Supreme Court on Tuesday invalidated two Prometheus Laboratories Inc. patents for a test that helps doctors set drug dosages for patients with Crohn's disease. The case was considered a key test of how far companies can go in patenting medical diagnostic tests, which can be used to screen patients for diseases and test whether a person can benefit from a particular treatment. The high court, in a unanimous ruling by Justice Stephen Breyer, said the patents were invalid because they made claims on laws of nature, which aren't patentable. The ruling was a win for the Mayo Clinic, which wants to offer a competing medical test. Mayo argued the Prometheus patents improperly sought to claim a patent monopoly on the right to observe a natural phenomenon: how the human body reacts to ingesting certain drugs. Leading medical groups supported Mayo in the case, arguing that no one should enjoy exclusive patent rights to tests that observe the human body's natural response to illness or treatments. The ruling was a setback for biotechnology and drug companies such as Roche Holding AG (RHHBY, ROG.VX) and Abbott Laboratories (ABT), which argued that such patents are key to protecting investments in medical advances. Prometheus is a unit of Nestle S.A. (NSRGY, NESN.VX). Among the best known of the patents are those held by Myriad Genetics Inc. (MYGN) that allow the company to be the exclusive provider of screening tests that identify patients at risk for breast and ovarian cancers. Those patents are also being challenged in court. The case is Mayo Collaborative Services v. Prometheus Laboratories Inc., 10-1150. --By Brent Kendall, Dow Jones Newswires; 202-862-9222;

Stock News for Abbott Labs (ABT)
10/26/201616:11:00St. Jude Medical Shareholders Approve Merger with Abbott
10/26/201614:00:00New Study: Babies Fed Infant Formula with 2'-FL Human Milk Oligosaccharide...
10/24/201617:05:03Current Report Filing (8-k)
10/20/201611:17:00People's Republic of China Clears Abbott Acquisition of Alere
10/20/201603:03:00Business Watch -- WSJ
10/19/201614:52:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake...
10/19/201612:18:00St. Jude Medical's Sales Rise 12% -- Update
10/19/201610:23:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake--Update
10/19/201610:10:00St. Jude Medical's Sales Rise 12%
10/19/201609:53:00St. Jude Medical's Sales Rise 12%
10/19/201609:50:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201609:43:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201607:53:35Current Report Filing (8-k)
10/19/201607:45:00Abbott Reports Third-Quarter 2016 Results
10/18/201609:20:00Abbott, St. Jude Medical to Sell $1.1 Billion in Assets
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/17/201622:10:00St. Jude Medical Forms Cybersecurity Advisory Group
10/17/201621:20:00St. Jude Medical Forms Cybersecurity Advisory Group
10/14/201611:15:00The Innovation of Wearable Technology and Medical Devices

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations